Filing identity and reporting period
The supplied filing is Colfax Corporation’s Form 10-K for the fiscal year ended December 31, 2019, filed February 21, 2020. The request metadata identifies “Enovis CORP” and “2019 Q4,” but the filing itself concerns Colfax and presents full-year results, with unaudited fourth-quarter data separately disclosed.
Business context
Colfax operated through Fabrication Technology, principally under the ESAB brand, and Medical Technology, principally under the DJO brand. The company completed the $3.15 billion acquisition of DJO on February 22, 2019 and sold its Air and Gas Handling business on September 30, 2019 for total consideration of approximately $1.8 billion, including $1.67 billion of cash at closing. Air and Gas Handling is reported as discontinued operations.
Management described the resulting portfolio as less cyclical, higher margin and supported by more stable cash generation. Approximately 56% of 2019 sales came from operations outside the United States, and the company employed approximately 15,000 people at year-end.
Key financial metrics
| Metric | 2019 | 2018 |
|---|---|---|
| Net sales from continuing operations | $3.327 billion | $2.193 billion |
| Gross profit | $1.401 billion | $729.4 million |
| Gross margin | 42.1% | 33.3% |
| Operating income | $203.6 million | $151.5 million |
| Operating margin | 6.1% | 6.9% |
| Net income from continuing operations | $18.9 million | $121.9 million |
| Continuing-operations diluted EPS | $0.10 | $1.00 |
| Net income attributable to Colfax | $(527.6) million | $140.2 million |
| Consolidated diluted EPS | $(3.89) | $1.16 |
| Net cash provided by operating activities | $130.9 million | $226.4 million |
| Capital expenditures | $125.4 million of purchases in cash-flow presentation | $69.6 million |
Management’s non-GAAP Adjusted EBITA increased to $476.9 million from $227.3 million, and Adjusted EBITA margin increased to 14.3% from 10.4%. These measures exclude, among other items, restructuring, strategic transaction costs, acquisition-related amortization and other non-cash charges, pension settlement loss, interest and taxes.
Fourth-quarter 2019 data
| Metric | Q4 2019 | Q4 2018 |
|---|---|---|
| Net sales | $888.4 million | $574.9 million |
| Gross profit | $395.8 million | $181.6 million |
| Net income from continuing operations | $34.4 million | $36.6 million |
| Net loss attributable to Colfax | $(16.9) million | $45.9 million income |
| Consolidated diluted EPS | $(0.12) | $0.39 |
Liquidity, debt and balance sheet
- Cash and cash equivalents were $109.6 million at December 31, 2019. The filing also presents $245.0 million of comparative cash including amounts associated with the Air and Gas Handling business classified as held for sale.
- Total debt increased to $2.312 billion from $1.197 billion, primarily because of financing for the DJO acquisition. Long-term debt was $2.284 billion.
- The December 2019 credit facility amendment reduced revolving commitments to $975 million and extended the Revolver and Term A-1 maturity to December 6, 2024. Revolver availability was $925 million at year-end, and the weighted-average credit-facility borrowing rate was 3.35%.
- Colfax used approximately $1.65 billion of Air and Gas Handling sale proceeds to repay term loans and revolving debt. The company stated that it was in compliance with its debt covenants and believed liquidity sources were adequate for the following twelve months.
- Outstanding letters of credit were $153.4 million against aggregate facilities of $416.2 million. Unconditional supplier purchase obligations were $292.2 million, and operating lease obligations totaled $205.5 million.
Material changes versus the prior comparable period
- Sales increased 51.7%, almost entirely reflecting the DJO acquisition and other acquisitions; foreign-currency translation reduced reported sales by approximately $87.1 million.
- Medical Technology contributed $1.080 billion of sales for the approximately ten months owned, with 4.4% organic growth on the comparable post-acquisition basis. Its Adjusted EBITA margin was 18.4%.
- Fabrication Technology sales increased 2.5% to $2.247 billion. Segment operating margin improved to 13.5% from 11.4%, supported by pricing, restructuring benefits and acquisitions, partly offset by modestly lower volumes and foreign exchange.
- Continuing-operations net income declined by $103.0 million because of higher acquisition-related amortization and other non-cash charges, restructuring charges, strategic transaction costs, interest expense and a pension settlement loss.
- Operating cash flow declined by $95.4 million. Working capital consumed $114.3 million, including approximately $40 million of one-time actions to normalize DJO supplier payment terms and eliminate a DJO receivables-factoring program.
- Research and development expense increased to $61.8 million from $34.2 million.
Unusual items, outlook and risks
- The Air and Gas Handling divestiture generated a $536.0 million after-tax loss from discontinued operations, including a $449 million goodwill impairment charge, $48.6 million of divestiture-related expense, $47.6 million of allocated interest expense, a $43.8 million pension settlement loss and $44.1 million of income tax expense. This drove the consolidated annual loss.
- Restructuring and other related charges were $73.7 million, strategic transaction costs were $61.0 million, acquisition-related amortization and other non-cash charges were $138.5 million, and the pension settlement loss was $33.6 million in continuing operations.
- Management expected long-term organic growth from orthopedic-care secular trends, including aging populations and increased outpatient procedures, while seeking further margin improvement through the Colfax Business System, cost rationalization and acquisitions. No specific numerical revenue or earnings guidance was provided in the filing.
- Key risks include integration of DJO and realization of expected synergies, high leverage and variable-rate debt, cyclical industrial demand, foreign exchange, raw-material costs and tariffs, medical-device regulation and reimbursement, product liability, cybersecurity, manufacturing disruptions and pension funding.
- Asbestos liabilities totaled $350.5 million, partially offset by reported insurance assets and receivables. Management estimates future claims only over a 15-year period; actual claims, settlement costs, insurer solvency and recoveries could differ materially.
- The company had $3.2 billion of goodwill and $193.5 million of indefinite-lived trade names subject to impairment review. No impairment was identified for the continuing Fabrication Technology or Medical Technology reporting units at year-end.
- DJO represented 52% of total assets, 32% of total sales and 22% of total operating income for 2019. Management and the external auditor excluded DJO from the 2019 internal-control assessment while integration proceeded; the auditor nevertheless reported effective company-wide internal control and issued an unqualified financial-statement opinion.
Investor verification points
- Confirm the intended issuer: the source filing is Colfax Corporation, not Enovis CORP.
- Reconcile fourth-quarter figures with the full-year results and confirm that Air and Gas Handling is excluded from continuing operations for all presented periods.
- Assess DJO’s organic growth, margin trajectory, integration costs and the sustainability of the reported 18.4% Adjusted EBITA margin.
- Review debt maturities, covenant headroom, variable-rate exposure and the company’s ability to reduce leverage after the DJO acquisition.
- Separate recurring operating performance from the $481 million divestiture impairment, $73.7 million restructuring charges, $61.0 million transaction costs and pension settlement losses.
- Evaluate asbestos-liability assumptions, insurance recoverability and the pending insurer-coverage litigation.
- Consider the effect of foreign exchange, tariffs, medical reimbursement changes and regulatory requirements on future sales and margins.